Skip to main content
Fig. 3 | Journal of Experimental & Clinical Cancer Research

Fig. 3

From: Rhein sensitizes human pancreatic cancer cells to EGFR inhibitors by inhibiting STAT3 pathway

Fig. 3

Combined rhein and EGFR inhibitors synergistically suppress pancreatic cancer cell proliferation. a PANC-1 cells were treated with serial dilutions of rhein, the EGFR inhibitor afatinib or the combination of rhein plus afatinib. Cell viability was measured after 2 days of treatment by the MTT assay. Survival rates were plotted using the GraphPad Prism software. CompySyn was used for determining the combination index. b The PANC-1 cells were treated with rhein, erlotinib or the combination. c The PANC-1 cells were treated with serial dilutions of rhein, gefitinib or the combination. d The AsPC-1 cells were treated with serial dilutions of rhein, erlotinib or the combination. e Colony forming assay in PANC-1 cells. Data are expressed as mean ± SD. Experiments were performed in triplicate and were independently repeated three times. *p < 0.05, **p < 0.01, ***p < 0.001, ****p<0.0001

Back to article page